Naphazoline
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Naphazoline: From Nasal and Ocular Decongestion to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Naphazoline is a topical alpha-adrenergic vasoconstrictor used as a nasal and ocular decongestant (it reduces redness and swelling by narrowing blood vessels). The TxGNN model predicts it may be effective for hypotrichosis simplex of the scalp, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore license records (the product types are nasal spray, nebuliser and ophthalmic solution; reduction of eye redness is the known clinical use) |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.83% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled records. From pharmacology data, naphazoline binds alpha-1A, alpha-2A and alpha-2C adrenoceptors. It is a vasoconstrictor that temporarily reduces eye redness by narrowing swollen blood vessels.
The prediction is not well supported mechanistically. Hypotrichosis simplex of the scalp is a genetic hair disorder, and no known mechanism links alpha-adrenergic vasoconstriction to hair follicle growth. Vasoconstriction could even reduce scalp blood flow, the opposite of what a hair-growth agent needs. The high TxGNN score most likely reflects proximity in the knowledge graph rather than pharmacology.
The other top-ranked predictions show the same pattern. They are mostly hair-related conditions (congenital hypotrichosis milia, diffuse alopecia areata, alopecia, hypertrichosis) and rare congenital syndromes, none with a plausible mechanism. The two glaucoma predictions (primary hereditary glaucoma and open-angle glaucoma) have a plausible ocular route, but they also carry a safety concern (see below).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the top predicted indication.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN03722P | NAZAL SPRAY | Spray | Not stated in records |
| SIN07343P | FLUCUR NEBULISER | Spray | Not stated in records |
| SIN04717P | NAPHCON-A STERILE OPHTHALMIC SOLUTION | Solution | Not stated in records |
All three licenses are valid single-ingredient products.
Safety Considerations
- Disease-related cautions from the knowledge graph (drug-disease contraindication links in the TxGNN knowledge graph, not label text):
- Cardiovascular: hypertension, hypertensive disorder, cardiovascular disease, heart disease
- Metabolic and endocrine: hyperglycaemia, diabetes mellitus, diabetic ketoacidosis, hyperthyroidism, Graves disease, thyrotoxicosis
- Ocular: angle-closure glaucoma, closed-angle glaucoma, eye infectious disease, conjunctivitis
- Relevance to glaucoma predictions: alpha-agonists can cause pupil dilation, which carries a risk of angle closure in susceptible eyes. Any glaucoma use would need to overcome this concern.
- Drug Interactions: Pharmacology data show naphazoline acts on alpha-1A, alpha-2A and alpha-2C adrenoceptors (human) and a mouse trace amine receptor (Taar4). No drug-drug interaction levels were reported.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is computational only (L5), with no clinical trials or relevant publications. The pharmacology argues against a hair-growth effect, and the opposite effect (reduced perfusion) is plausible. For the glaucoma-related predictions, the only retrieved paper concerns topical corticosteroids, not naphazoline, and angle-closure warnings are a safety concern.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Approved indication text for the three Singapore licenses
- Any direct preclinical or clinical evidence of naphazoline in hair disorders or glaucoma; without it, the prediction should not advance
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.